SCHEMBL20071775

SCHEMBL20071775

Cc1cc2c(cc1C)N(c1ccc(C(C)(C)C)s1)C(C1N(c3ccc(C(C)(C)C)s3)c3cc(C)c(C)cc3N1c1ccc(C(C)(C)C)s1)N2c1ccc(C(C)(C)C)s1

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.32
KMT2A Q03164 1/20 0.32
YEATS4 O95619 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20071773 0.84 MAPT (0.34) MAPK1KMT2A
SCHEMBL20062961 0.81 MAPK1 (0.33) MAPK1KMT2AYEATS4
SCHEMBL20072058 0.79 PTGS1 (0.32)
SCHEMBL20071952 0.76 RXRB (0.32)
SCHEMBL20062963 0.65 MAPT (0.31) MAPK1KMT2A
SCHEMBL47581 0.63 MAPK1 (0.45) MAPK1KMT2AYEATS4
SCHEMBL20071766 0.63 HSD17B10 (0.33)
SCHEMBL20071774 0.63 AR (0.38) MAPK1
SCHEMBL20681852 0.61 GAA (0.32)
SCHEMBL20681909 0.61 MAPK13 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10541260-B2 Organic photoelectric conversion element, optical area sensor, imaging device, and imaging apparatus CANON KABUSHIKI KAISHA (JP) 2020-01-21 US disclosed
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same CANON KABUSHIKI KAISHA (JP) 2019-01-29 US disclosed
US-20180108691-A1 ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS CANON KABUSHIKI KAISHA (JP) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same BRD1, DRD1, NR2E3 MAPK1 1515/4885KMT2A 2024/4885YEATS4 2085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.